Moderna and Merck published a joint press release announcing the interim results of the Phase III clinical trials for autogeneic intismeran. This development is an individualized neoantigen RNA vaccine designed to prevent melanoma recurrence.
Although final data has not yet been obtained, both companies state that the study has already demonstrated compliance with predefined success metrics during the planned preliminary analysis. These criteria relate to two aspects: the duration of patients' lives without disease recurrence and survival without the appearance of distant metastases.